Last reviewed · How we verify

EVOREL® CONTI — Competitive Intelligence Brief

EVOREL® CONTI (EVOREL® CONTI) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormone replacement therapy (HRT) — combined estrogen/progestin. Area: Endocrinology / Women's Health.

marketed Hormone replacement therapy (HRT) — combined estrogen/progestin Estrogen receptors (ER-α, ER-β) and progesterone receptor (PR) Endocrinology / Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

EVOREL® CONTI (EVOREL® CONTI) — Royal Brompton & Harefield NHS Foundation Trust. EVOREL CONTI is a transdermal patch that delivers continuous estradiol and norethisterone to provide hormone replacement therapy for menopausal symptoms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
EVOREL® CONTI TARGET EVOREL® CONTI Royal Brompton & Harefield NHS Foundation Trust marketed Hormone replacement therapy (HRT) — combined estrogen/progestin Estrogen receptors (ER-α, ER-β) and progesterone receptor (PR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hormone replacement therapy (HRT) — combined estrogen/progestin class)

  1. Royal Brompton & Harefield NHS Foundation Trust · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EVOREL® CONTI — Competitive Intelligence Brief. https://druglandscape.com/ci/evorel-conti. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: